Tim J. Akhurst

机构：The University of Melbourne, Peter MacCallum Cancer Centre

发表论文 117 篇 · 总被引 7262 次 · h-index 39

代表论文

• PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial (2022 · The Lancet Oncology · 被引 291)
• Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177 Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer (2019 · Journal of Nuclear Medicine · 被引 289)
• Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial (2023 · The Lancet Oncology · 被引 225)
• Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy (2018 · European Urology Oncology · 被引 187)
• Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617 (2020 · European Journal of Nuclear Medicine and Molecular Imaging · 被引 166)
• Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol (2019 · Thyroid · 被引 123)